(NP (-LRB- -LCB-) (NP (JJ Age-related) (NNS changes)) (PP (IN in) (NP (NP (NP-COOD (NP (NN glucocorticoid)) (CC and) (NP (NN mineralocorticoid))) (NNS receptors)) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN of) (NP-COOD (NP (JJ healthy) (NNS persons)) (CC and) (NP (NP (NNS patients)) (PP (IN with) (NP (NN hypertension)))))))))) (-RRB- -RCB-))
(S (NP-SBJ (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN found) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN number)) (PP (IN of) (NP (NN glucocorticoid) (NNS receptors))) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN of) (NP (NP (DT the) (JJ peripheral) (NN blood)) (PP (IN of) (NP (JJ healthy) (JJ elderly) (NNS subjects)))))))) (VP (VBZ increases) (, ,) (SBAR (IN while) (S (NP-SBJ (NP (DT the) (NN number)) (PP (IN of) (NP (NN mineralocorticoid) (NNS receptors)))) (VP (VBZ decreases)))))))))) (. .))
(S (S (NP-SBJ-20 (NP (DT The) (NNS mechanisms)) (PP (IN of) (NP (NN hormone-receptor) (NNS interactions))) (PP (IN in) (NP (NN hypertension)))) (VP (VBP are) (VP (VBN activated) (NP (-NONE- *-20)))) (: :)) (S (NP-SBJ (NP (DT the) (NN number)) (PP (IN of) (NP (NP-COOD (NP (NN glucocorticoid)) (CC and) (NP (NN mineralocorticoid))) (NN binding) (NNS sites)))) (VP (VBZ grows) (PP (IN in) (NP (JJ hypertensive) (NNS patients)))) (. .)))
(S (ADVP (RB Still)) (NP-SBJ-21 (NP (DT a) (ADJP (RBR more) (JJ essential)) (NN rise)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS receptors))))) (PP (-NONE- *ICH*-105))) (VP (VBZ is) (VP (VBN observed) (NP (-NONE- *-21)) (PP (IN in) (NP (JJ mid-age) (NN hypertensive) (NNS patients))) (PP-105 (IN than) (FRAG (PP (IN in) (NP (JJ elderly) (NNS ones))))))) (. .))
